Effectiveness of Telmisartan on Blood Pressure Control in Hypertensive Patients in India: A Real-World Retrospective Study from Electronic Medical Records

Abstract

Introduction: The effectiveness of telmisartan has been reported in Indian clinical trials; however, real-world data are limited. We aimed to provide real-world evidence regarding the effectiveness of telmisartan as monotherapy or in combination with other antihypertensive drugs (AHDs) in Indian patients with essential hypertension. Methods: Electronic medical record data of adult patients diagnosed with essential hypertension (C 140/90 mmHg) and who were prescribed telmisartan as mono-or add-on therapy were retrospectively analyzed. Patients were classified according to the number of AHD classes prescribed on initiating telmisartan. Change in systolic and diastolic blood pressure (SBP and DBP) after a month of treatment and the proportion of patients who achieved treatment goals according to the 2018 European Society of Cardiology/European Society of Hypertension guidelines were evaluated. Results: A majority (90.6%) of the 1304 patients included in the study were on telmisartan monotherapy or telmisartan ? 1 AHD. The mean (95% confidence interval [CI]) change in the telmisartan monotherapy group was SBP (-13.3 [-14.6, -12.0] mmHg) and DBP (-7.2 [-7.9, -6.5] mmHg), and the mean (95% CI) change in the telmisartan ? 1 AHD group was SBP (-10.8 [-13.1, -8.5] mmHg) and DBP (-6.5 [-7.7, -5.3] mmHg) (P \ 0.001 for all). SBP and DBP goals were achieved by 35.9% and 47.3% of patients on telmisartan monotherapy and by 35.9% and 46.8% of patients on telmisartan ? 1 AHD. Among patients with comorbid diabetes, the mean (95% CI) change in the telmisartan monotherapy group was SBP (-13.3 [-15.0, -11.6] mmHg) and DBP (-7.3 [-8.2, -6.5] mmHg), and the mean (95% CI) change Suyog Mehta was an employee of Dr. Reddy's Laboratories when the study was conducted

Blood pressure-lowering effect of telmisartan compared to losartan among mild to moderate essential hypertensive adult subjects: A meta-analysis

“…Telmisartan is also an effective BP-lowering agent when given alone or in combination during day-to-day practice for Asian hypertensive patients with comorbidities like diabetes or dyslipidemia. [ 27 ] Effectiveness of telmisartan in diabetics is also supported by one animal study which shows that telmisartan works through voltage-dependent potassium channel also. [ 28 ] …”

Monitoring Kidney Function Through the Use of Candesartan, Telmisartan or Valsartan Antihypertensive Therapy towards Patients CKD

“…24 Other studies have also suggested that ARBs have renoprotection and this effect of telmisartan appears to be stronger than Losartan, Candesartan, or Olmesartan in the early stage of DN patients. 25 There are also studies that show the results that creatinine is "significantly reduced by 18% from baseline (p<0.05). On the use of telmisartan 40 mg once daily for 12 months and the reduction was significantly greater than in the amlodipine group (p<0.05).…”

“…Lipophilicity of the active molecule is essential for distribution in the body. 25 A recent meta-analysis of 20 randomized controlled trials of telmisartan performed primarily in diabetic patients concluded that telmisartan therapy may be effective in easing proteinuria or preventing its development. Telmisartan caused statistically significant reductions in percent change in urinary albumin/protein excretion and urinary albumin/protein to creatinine to telmisartan ratio relative to ARBs, AFIs, and other therapies by 20, 14, and 40%.…”

Effect of combined use of home blood pressure monitoring and nifedipine on blood pressure compliance and quality of life of patients with essential hypertension

“…This indicates that although there are many types of drugs for treatment of hypertension in China, the blood pressure compliance has not been significantly improved. The 2010 Chinese Guidelines for the Management of Hypertension proposes that effective management is key to prevention of serious cardiovascular and cerebrovascular complications [5,6].…”